CN105732522A - Medicine composition for treating periodontitis - Google Patents
Medicine composition for treating periodontitis Download PDFInfo
- Publication number
- CN105732522A CN105732522A CN201610070649.XA CN201610070649A CN105732522A CN 105732522 A CN105732522 A CN 105732522A CN 201610070649 A CN201610070649 A CN 201610070649A CN 105732522 A CN105732522 A CN 105732522A
- Authority
- CN
- China
- Prior art keywords
- compound
- periodontitis
- pharmaceutical composition
- treatment
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001245 periodontitis Diseases 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 title abstract description 5
- 229940079593 drug Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 241000607142 Salmonella Species 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000004531 microgranule Substances 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 3
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 229920001817 Agar Polymers 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 0 CCC(*C(C=C1C([C@](C)c2ccc(C)c(N)c2)=*C=*C1C1)=C1OCCC*1CCOCC1)=O Chemical compound CCC(*C(C=C1C([C@](C)c2ccc(C)c(N)c2)=*C=*C1C1)=C1OCCC*1CCOCC1)=O 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- -1 correctives Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a medicine composition for treating periodontitis.The medicine composition comprises an effective quantity of compound and a carrier acceptable in pharmacy.Please see the structure of the compound in the description.The compound has a remarkable effect on pathogenic bacteria causing periodontitis and can be developed into the new effective medicine composition in clinic.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition treating periodontitis.
Background technology
The chronic inflammatory disease of the periodontal tissue that periodontitis is mainly caused by local factor.Age of onset is later comparatively common with 35 years old.As gingivitis fails to treat in time, inflammation can be diffused into periodontal membrane, alveolar bone and cementum by gingiva to deep layer and develop into periodontitis.Owing to early stage is how easily out in the cold without obvious subjective symptoms, more serious in time having symptom, even can not retain tooth.Thus propaganda and education must be strengthened, make patient's early presentation and treatment in time.In the patient illness part secretions of periodontitis, find that Siberia Al Kut Salmonella ATCC49154 is also one of pathogenic bacterium therein in the recent period.
Summary of the invention
It is an object of the invention to provide a kind of pharmaceutical composition treating periodontitis.
In order to realize the purpose of the present invention, the present invention provides a kind of compound treating periodontitis, and this compound has having structure:
The present invention also provides for a kind of pharmaceutical composition treating periodontitis, and described pharmaceutical composition comprises the compound of effective dose and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizer or corrigent.
Preferably, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
Preferably, described diluent is lactose.
Preferably, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
The present invention also provides for compound purposes in the medicine of preparation treatment periodontitis, and this compound has having structure:
Preferably, described infection is caused by Siberia Al Kut Salmonella ATCC49154.
The present invention also provides for compound purposes in the medicine of preparation vitro inhibition Siberia Al Kut Salmonella ATCC49154, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to the material of biologic activity or the character not eliminating compound as herein described, such as carrier or diluent.This kind of material is applied to individuality and is not resulted in undesirable biological action or not with harmful way and any component interaction in the compositions comprising it.
" pharmaceutically acceptable carrier " includes any and all of solvent as the term is employed herein, disperse medium, coating material, surfactant, antioxidant, preservative (such as antibacterial, antifungal), isotonic agent, absorption delay agent, salt, preservative, drug stabilizing agent, binding agent, excipient, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with the inconsistent carrier of active component, consider to use any conventional carrier in treatment or pharmaceutical composition.
The compound of the present invention is notable for the pathogen effect causing periodontitis, it is possible to develop into pharmaceutical composition effectively new clinically.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art's basic thought according to the present invention, various modifications may be made or improves, but without departing from the basic thought of the present invention, all within the scope of the present invention.
The research of experimental example the compounds of this invention purposes in the medicine of preparation vitro inhibition Siberia Al Kut Salmonella ATCC49154
Bacteriostatic test
Use following compounds, adopt filter paper enzyme classical in this area to carry out bacteriostatic test, wherein:
The structural formula of target compound is:
For examination strain Siberia Al Kut Salmonella ATCC49154 purchased from Fu Xiang bio tech ltd, Shanghai.
Culture fluid
Nutrient agar and nutrient broth, purchased from Chen Yu experimental facilities company limited of BeiJing ZhongKe.
Test method
Siberia Al Kut Salmonella ATCC49154 is inoculated in agar plate nutritional solution plane, uniformly gathers during inoculation.
Weighing target compound 0.01 gram, add 25000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μm, obtained solution.The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritional solution plane of inoculated bacteria.Agar plate is placed in the incubator of 37 DEG C, incubation 4 hours.Measure the diameter of antibacterial ring.Measure and average for 3 times.
1.4 results
The average diameter of the antibacterial ring of Siberia Al Kut Salmonella ATCC49154 is 13.68mm, and this shows that target compound has the effect of extremely strong vitro inhibition Siberia Al Kut Salmonella ATCC49154.
Claims (9)
1. the compound treating periodontitis, it is characterised in that this compound has having structure:
2. the pharmaceutical composition treating periodontitis, it is characterised in that described pharmaceutical composition comprises the compound of effective dose and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of periodontitis according to claim 2, it is characterised in that described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizer or corrigent.
4. the pharmaceutical composition for the treatment of periodontitis according to claim 3, it is characterised in that described diluent is sugar derivatives, starch derivatives or cellulose derivative.
5. the pharmaceutical composition for the treatment of periodontitis according to claim 4, it is characterised in that described diluent is lactose.
6. the pharmaceutical composition for the treatment of periodontitis according to claim 3, it is characterised in that described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
7. compound purposes in the medicine of preparation treatment periodontitis, it is characterised in that this compound has having structure:
8. purposes according to claim 7, it is characterised in that described infection is caused by Siberia Al Kut Salmonella ATCC49154.
9. compound purposes in the medicine of preparation vitro inhibition Siberia Al Kut Salmonella ATCC49154, it is characterised in that this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610070649.XA CN105732522A (en) | 2016-02-01 | 2016-02-01 | Medicine composition for treating periodontitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610070649.XA CN105732522A (en) | 2016-02-01 | 2016-02-01 | Medicine composition for treating periodontitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105732522A true CN105732522A (en) | 2016-07-06 |
Family
ID=56242105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610070649.XA Pending CN105732522A (en) | 2016-02-01 | 2016-02-01 | Medicine composition for treating periodontitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105732522A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1160338C (en) * | 1998-11-19 | 2004-08-04 | 沃尼尔·朗伯公司 | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, irreversible inihibotr of tyrosine kinases |
-
2016
- 2016-02-01 CN CN201610070649.XA patent/CN105732522A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1160338C (en) * | 1998-11-19 | 2004-08-04 | 沃尼尔·朗伯公司 | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, irreversible inihibotr of tyrosine kinases |
Non-Patent Citations (2)
| Title |
|---|
| 吴云登等: "卡奈替尼的合成", 《中国医药工业杂志》 * |
| 肖晴等: "卡博替尼阻断小鼠体内产单核细胞李斯特菌感染的实验研究", 《南方医科大学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Al-Waili | Investigating the antimicrobial activity of natural honey and its effects on the pathogenic bacterial infections of surgical wounds and conjunctiva | |
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105198903A (en) | Pharmaceutical composition for treating acute upper respiratory infection | |
| CN105732522A (en) | Medicine composition for treating periodontitis | |
| CN104086541B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN105232540A (en) | Drug combination for treating infection after burn | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105232550B (en) | A kind of pharmaceutical composition treating chronic pelvic inflammatory disease | |
| CN105560234A (en) | Medicine composition for treating oral and maxillofacial inflammation | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105777612A (en) | Medicine composition for treating children recurrent respiratory infection | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105232504A (en) | Medicine composition for treating infant recurrent respiratory tract infections | |
| CN105348270A (en) | Medicine composition preventing dental body and dental pulp infection | |
| CN105687189A (en) | Medicine composition for treating upper respiratory tract infection | |
| CN105125546A (en) | Medicine composition for treating postoperative wound infection | |
| CN105330610A (en) | Medicine composition for treating gingivitis | |
| CN105254477A (en) | Medicine composition for treatment of vaginitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160706 |
|
| RJ01 | Rejection of invention patent application after publication |